CVS Health (CVS) Q3 FY2026 Earnings Call: Q&A Summary

Q: Lisa Gill with JPMorgan asked about the timing and rationale for separating the company after 20 years.

A: David Joyner, Chairman and CEO, stated that the decision is made from a position of strength following eight quarters of beat and raise results and ahead-of-schedule leverage reduction, noting that retail pharmacy has operated behind a firewall for two decades and that the separation will allow each business to pursue tailored capital allocation and move faster.

Q: Lisa Gill with JPMorgan asked if the 340B headwinds represent a change in contracting and why management has line of sight to it ending in 2027.

A: Brian Newman, CFO, noted that HSS performance was in line with expectations and established a floor of at least $7 billion in HSS AOI for next year. Prem Shah, Group President, added that 340B contribution in the 2027 plan is an even smaller portion of segment earnings, that the program will not fully go away, and that 2027 represents trough earnings before returning to growth.

Q: Justin Lake with Wolfe Research asked how the breakup impacts credit ratings, leverage metrics, and future share repurchases against the $35 billion deployable capital target.

A: Brian Newman, CFO, affirmed that both companies will be solid investment grade with strong free cash flow and appropriate leverage metrics, and confirmed that the share repurchase program will resume in the fourth quarter with nothing getting in the way of future capital deployment.

Q: Michael Cherny with Leerink Partners asked how the strategic rationale and overlap between CVS Pharmacy and Caremark will be handled post-split without losing competitive differentiation.

A: David Joyner explained that unique products built over the last 20 years will be preserved through commercial agreements between the two independent organizations, and that Mail Services is housed within CVS Pharmacy because pharmacy is organized around the consumer.

Q: Elizabeth Anderson with Evercore ISI asked where Prem Shah sees additional store-focused opportunities for the independent retail entity.

A: Prem Shah, Group President, highlighted prior investments in AI workflow supporting 85% of prescriptions, colleague enablement, and omnichannel customer satisfaction, noting 3.9% comp script growth and a 23% increase in GLP-1 scripts this quarter.

Q: Elizabeth Anderson asked for more details on underlying trend and strength in the Medicare Advantage business.

A: Steven Nelson stated that Aetna experienced pockets of favorability within a high trend environment, noted that 2027 pricing assumes elevated trends persist, and confirmed that levers including benefit adjustments, geographic mix, and star ratings are supporting another year of margin improvement.

Q: Erin Wilson Wright with Morgan Stanley asked about the rationale for retaining Specialty at CVS Health and long-term PBM synergies.

A: David Joyner explained that specialty drugs drive more than 50% of pharmacy spend from 2% of the population, requiring classic PBM levers to attack rising drug costs, and noted that Aetna and Caremark benefit from integrated management of total care and pharmacy costs.

Q: Stephen Baxter with Wells Fargo asked how management thinks about operating cost synergies or dis-synergies from the transaction.

A: Brian Newman responded that the strategic value created will far outweigh dis-synergies, and that public company and stranded costs are manageable, in line with similar transactions, and will be offset over time.

Q: Andrew Mok with Barclays asked whether the 2027 EPS floor of $8.65 assumes share repurchases and if any breakup costs are embedded.

A: Brian Newman confirmed that the $8.65 guidance floor only assumes the offset of dilution from share repurchases as cash and leverage targets are met.

Q: Ann Hynes with Mizuho asked if management is ready to provide growth algorithms for the two stand-alone companies post-separation.

A: Brian Newman stated they are tracking well against the mid-teens EPS CAGR road map to 2028 outlined at Investor Day and will provide more details on the 2027 guide and baseline during the February call.

Q: Scott Fidel with Goldman Sachs asked to confirm if Medicare Advantage has returned to profitability in 2026 and whether 2027 implies a multiyear path to target margins.

A: Steven Nelson confirmed that the Medicare business is moving into profitable territory in 2026 on its multiyear journey and that 2027 will see another year of targeted margin expansion through repricing and benefit design.

Q: George Hill with DB asked what changed in management's outlook over the past two years to enable the split and how each business becomes competitively advantaged.

A: David Joyner concluded that the split is possible because improved financial performance, a strengthened balance sheet, and retail recovery allow the decision to be made from a position of strength rather than distress, enabling each independent company to focus on its core market and technology adoption.